**Open For Enrollment**
Daiichi Sanyko – Protocol DS7011-107 – Phase 1b/2A double-blind Placebo controlled randomized, Parallel-Arm Study to explore the safety, Pharmacokinetics and Proof of Biological Activity of DS-7011a in patients with SLE and Active Cutaneous Lupus Erythematosus
**Open For Enrollment**
AstraZeneca – Protocol D3465C00001 – A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
**Open For Enrollment **
Allegory Roche – Protocol CA42750 – A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus”
**Open For Enrollment**
Gilead – Protocol GS-US-497-6486 – “A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof of-Concept Study to Evaluate Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)”
PATIENT INFORMATION DOCUMENTS
New Patient Information
